Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Heart disease is the leading cause of death worldwide. Despite decades of research, most
heart pathologies have limited treatments, and often the only curative approach is heart …

Homeostatic regulation of cardiomyocytes plays a crucial role in maintaining the normal
physiological activity of cardiac tissue. Severe cardiotoxicity results in cardiac diseases …

Damage to organs by trauma, infection, diseases, congenital defects, aging, and other
injuries causes organ malfunction and is life-threatening under serious conditions. Some of …

Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …

Background: The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic
myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance …

The BCR–ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic
leukemia in Ph+ patients because the ABL kinase is constitutively activated. However …

Long-term cardiovascular complications of cancer therapy are becoming ever more
prevalent due to increased numbers of cancer survivors. Cancer therapy-induced …